SCHEMBL318924

SCHEMBL318924

CCOC(=O)c1csc(-c2c(F)cccc2F)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.57
NPC1 O15118 7/20 0.57
MAPT P10636 5/20 0.57
POLB P06746 1/20 0.57
PKM P14618 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
RXFP1 Q9HBX9 1/20 0.57
ALDH1A1 P00352 2/20 0.55
GAA P10253 2/20 0.54
CYP1A2 P05177 2/20 0.53
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
PIM1 P11309 5/20 0.49
PIM3 Q86V86 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CLK1 P49759 1/20 0.48
CYP2C19 P33261 1/20 0.48
CYP19A1 P11511 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
HSP90AA1 P07900 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL793414 0.91 RAB9A (0.53) RAB9ANPC1MAPTPOLBPKM
SCHEMBL318683 0.87 RAB9A (0.55) RAB9ANPC1MAPTPOLBPKM
SCHEMBL26319815 0.86 RAB9A (0.60) RAB9ANPC1MAPTPOLBPKM
SCHEMBL29600613 0.85 MAOA (0.57) PIM1PIM3PIM2
SCHEMBL793051 0.84 RAB9A (0.58) RAB9ANPC1MAPTPOLBPKM
SCHEMBL13144514 0.82 MAPT (0.70) RAB9ANPC1MAPTPOLBPKM
SCHEMBL11912168 0.80 PIM1 (0.55) PIM1PIM3PIM2
SCHEMBL31163885 0.80 RAB9A (0.69) RAB9ANPC1MAPTPOLBPKM
SCHEMBL3103929 0.79 MAPT (0.56) RAB9ANPC1MAPTPOLBPKM
SCHEMBL2080725 0.79 RAB9A (0.68) RAB9ANPC1MAPTPOLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4186897-A1 PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR Incyte Holdings Corporation (US) 2023-05-31 EP disclosed
EP-4186897-A1 PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR Incyte Holdings Corporation (US) 2023-05-31 EP disclosed
EP-3670506-B1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE HOLDINGS CORP (US) 2023-01-04 EP disclosed
EP-3670506-B1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE HOLDINGS CORP (US) 2023-01-04 EP disclosed
CN-108715590-B Thiazolecarboxamide and picolinamide compounds useful as PIM kinase inhibitors 因赛特公司 2022-03-08 CN disclosed
US-11229631-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors INCYTE CORPORATION (US) 2022-01-25 US disclosed
US-11229631-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors INCYTE CORPORATION (US) 2022-01-25 US disclosed
US-20200405702-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION 2020-12-31 US disclosed
US-20200405702-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION 2020-12-31 US disclosed
US-10828290-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors INCYTE CORPORATION (US) 2020-11-10 US disclosed
US-8168794-B2 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-05-01 US disclosed
US-8168794-B2 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-05-01 US disclosed
WO-2012004217-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-12 WO disclosed
WO-2012004217-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-12 WO disclosed
EP-2262802-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2010-12-22 EP disclosed
US-20100216839-A1 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-26 US disclosed
US-20100216839-A1 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-26 US disclosed
US-20100216839-A1 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-26 US disclosed
WO-2009109576-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2009-09-11 WO disclosed
WO-2009109576-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216839-A1 Pim kinase inhibitors and methods of their use PIM1, PIM2, PIM3 RAB9A 3326/4885NPC1 1582/4885MAPT 978/4885
US-20200405702-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS PIM2, PIM1, PIM3 RAB9A 4447/4885NPC1 2615/4885MAPT 3436/4885
US-11229631-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors PIM2, PIM1, PIM3 RAB9A 4447/4885NPC1 2615/4885MAPT 3436/4885
US-10828290-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors PIM2, PIM1, PIM3 RAB9A 4447/4885NPC1 2615/4885MAPT 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.